On the other hand, for patients receiving pembrolizumab, both positive ANA and age were found to be potential risk factors for ICIS-related hepatitis (risk ratios 7.834: 95% CI 1.743-35.21: p=0.0073 and 0.896: 95% CI 0.896: p=0.0050, respectively) 101. The gene discussed is BTG3; the disease is Hepatitis.